Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood


13 Apr 2018


New approaches in rare thoracic tumors


Ferdinando Cerciello


Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.


F.W.F. Cerciello1, M. Choi2, S.L. Sinicropi-Yao1, E. Felley-Bosco3, R.A. Stahel4, B. Robinson5, J. Creaney5, H.I. Pass6, O. Vitek2, D.P. Carbone1

Author affiliations

  • 1 James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, 43210 - Columbus/US
  • 2 College Of Science, College Of Computer And Information Science, Northeastern University, Boston/US
  • 3 Laboratory Of Molecular Oncology, Division Of Thoracic Surgery, University Hospital Zürich, 8044 - Zürich/CH
  • 4 Department of Oncology, Center of Hematology and Oncology, Cancer Center Zürich, University Hospital Zürich, 8091 - Zürich/CH
  • 5 National Centre For Asbestos Related Disease, University of Western Australia, School of Medicine and Pharmacology, Nedlands/AU
  • 6 Langone Medical Center New York, New York University, New York/US


Blood biomarkers are not routinely applied for the diagnosis of malignant pleural mesothelioma (MPM). We investigated a multiplexed biomarkers signature composed of 6 glycopeptides for the diagnosis of MPM in blood using mass spectrometry based targeted proteomics.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings